LEADS BIOLABS-B (09887.HK): Phase II study abstract of Vimx (opasumivimab) as first-line NSCLC therapy published on WCLC website

NewTimeSpace News: On 20 August 2026, Nanjing Leads Biolabs Co., Ltd. (stock code: 09887) announced in a voluntary announcement that the full abstract of its Phase II clinical study of Vimx™ (opasumivimab, a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC) has been officially published on the website of the World Conference on Lung Cancer (WCLC).

According to the announcement, based on the data analysis as of 6 March 2026, Vimx™ combined with chemotherapy demonstrated an objective response rate (ORR) of 65.0% and a disease control rate (DCR) of 95.0% in 60 efficacy-evaluable patients; in the squamous subgroup, ORR was 77.4% and DCR 96.8%, while in the non-squamous subgroup, ORR was 51.7% and DCR 93.1%, with manageable overall safety and no new safety signals observed. The abstract data is based on a follow-up of only 3.6 months, with the latest data from follow-up exceeding seven months to be presented in the oral presentation session at WCLC on 14 September 2026.

The announcement states that Vimx™ is the world's first molecule targeting the costimulatory receptor 4-1BB at the single-arm pivotal registration clinical stage, having received breakthrough therapy designation from the CDE of the NMPA in October 2024, US FDA orphan drug designation in November 2024, and FDA fast track designation and EU orphan drug designation in January 2026; it is currently conducting clinical studies across 13 solid tumor indications in China, covering high unmet medical need areas including NSCLC, SCLC, EP-NEC and BTC. Under Rule 18A.05 of the Listing Rules, the Company cannot guarantee successful development or eventual commercialization of Vimx™.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.